



中国艾滋病性病

ZHONGGUO AIZIBING XINGBING

CHINESE JOURNAL OF AIDS & STD

2020年 第26卷 第3期 (总第198期)
Vol.26 No.03 (Serial No.198)



F5000



中文核心期刊

中国科技核心期刊

百种中国杰出学术期刊

RCCSE中国核心学术期刊

美国化学文摘(CA)及数据库收录

国家科技部中国科技论文统计源期刊

ISSN 1672-5662



9 771672 566200



03>

中国性病艾滋病防治协会主办

万方数据

中国艾滋病性病

CHINESE JOURNAL OF AIDS & STD

月刊 1995年8月创刊 第26卷 第3期 总第198期 2020年3月26日出版

主 管

国家卫生健康委员会

主 办

中国性病艾滋病防治协会
北京市西城区南纬路27号 100050

编辑出版

《中国艾滋病性病》杂志编辑部
北京市西城区南纬路27号 100050
电话: 010-63030828
传真: 010-63030028
Email: aids2006@sina.com
aidsbjb@126.com

主 编

沈 洁

编辑部主任

刘 霞

印 刷

北京市十月印刷有限公司
北京市通州区马驹桥民族
工业园9号 101102

发 行

国内: 中国邮政集团公司
北京分公司
国外: 中国国际图书贸易集团
有限公司
(北京399信箱, 100044)
国外代号: M6559

订 购

全国各地邮电局
邮发代号: 82-912

定 价

每期20.00元, 全年240.00元

国际标准连续出版物号

ISSN 1672-5662

国内统一连续出版物号

CN 11-4818/R

2020年经作者授权后, 版权归中国
性病艾滋病防治协会所有

除非特别声明, 本刊刊出的所有文章
不代表本刊编委会的观点

目 次

论 著

- 不同病程状态 HIV/AIDS 病人的 HIV 总 DNA 比较研究
.....刘佳, 闫江舟, 薛秀娟, 刘春华, 孙国清, 田随安, 孙定勇, 王哲 (227)
- HIV 感染者外周血单个核细胞中 HIV DNA 载量与 HIV RNA 及
CD4⁺ T 淋巴细胞间的关系.....潘克女, 张永乐, 郁文燕, 薛立芝 (231)
- 抗结核治疗对 HIV/AIDS-TB 病人抗病毒治疗效果的影响.....舒远路,
杨翠先, 董兴齐, 张米, 李健健, 杨壁琿, 刘家法, 邓雪媚, 张玮, 严妍 (234)
- 艾滋病高流行地区 HIV 感染者结核潜伏性感染诊断方法比较...黄欢, 高文凤,
苏茜, 李京, 李婷, 李运葵, 汪川, 高媛, 徐进川, 廖志鸿, 何金戈, 杨文 (239)
- 互联网上销售的 HIV 抗体快速检测试剂物理性能和灵敏度调查
.....任雅楠, 马仲慧, 徐冰, 王俊, 裴丽健, 蒋岩, 邢文革 (243)
- 医疗机构丙型肝炎诊断治疗现状研究
.....冯小飞, 丁国伟, 俞海亮, 潘玲, 高榆, 汤杨, 毛宇嵘, 庞琳 (247)
- 浙江省 4 家综合性医院就诊者丙型肝炎病毒抗体检测结果分析
.....蒋均, 潘晓红, 杨介者, 洪航, 许圆圆, 王斌, 石小俊, 叶小红, 陈巧明 (250)
- HIV 感染孕妇耐药状况的 Meta 分析
.....沈蕊, 潘晓平, 王爱玲, 王潇滢, 屈水令, 张彤 (254)
- 我国三城市青年学生艾滋病非职业暴露后药物预防知识知晓和
接受服务情况.....邵英, 李杰, 刘安,
于艳平, 陈子亮, 姜天俊, 宋兵, 王辉, 刘晓宁, 刘俊, 张广 (259)
- 2009 — 2018 年深圳市 HIV 阳性孕产妇特点及母婴阻断效果分析
.....田一梅, 梁梅馨, 宋俊敏, 杨峥嵘, 周洁, 王红, 包明稳, 王辉 (264)
- 北京男男性行为者 HIV-1 基因多样性及相关因素研究.....周知涵, 张晶,
辛若雷, 阮玉华, 卢红艳, 冯毅, 康瑞华, 廖玲洁, 邵一鸣, 邢辉 (268)
- 广东省男男性行为者 HIV-1 传播特征
.....周平平, 于国龙, 刘珺, 付笑冰, 李艳, 黄旭和, 林鹏, 颜瑾, 何翔 (273)
- 绵阳市男男性行为者参加艾滋病防治社区活动及关联因素分析
.....王毅, 李六林, 樊静, 赵西和,
王晓丽, 李俊, 杨千金, 李伟, 贾修伟, 刘晓琴, 杜婵娟, 任延飞, 廖平 (277)
- 常德和张家界两市 HIV 阳性已婚男男性行为者性行为状况分析
.....黄道平, 池媛媛, 周婧, 黎雅娟, 李现红 (281)
- 191 例男男性行为者的 HIV 感染者儿童期创伤对其精神病性
体验的影响...王东方, 周柏, 高钰激, 杨新华, 王敏, 欧阳萱, 刘哲宁, 王红红 (286)
- 武汉市 2008 — 2018 年报告 HIV/AIDS 病人晚发现状况及影响因素
.....丁洁, 闫晗, 吴斯, 王夏, 谢年华 (290)
- 云南摩梭居民艾滋病相关知识行为及 HIV 感染现况调查.....宋丽军,
张绪宏, 陆雁宁, 沙鹏莲, 肖民扬, 付丽茹, 牛瑾, 李雪华, 罗红兵 (294)

《中国艾滋病性病》杂志
第五届编辑委员会名单

名誉主编：戴志澄
主 编：沈 洁
副 编：张孔来 康来仪
邱泽奇

副 主 编：汪 宁（常务）
（以姓氏笔画为序）
王 健 王福生 李太生
吴 昊 张林琦 张福杰
邵一鸣 尚 红 顾 恒
程锦泉

常务编委：（以姓氏笔画为序）
王晓春 王爱玲 卢洪洲
吕 繁 伦文辉 刘 霞
孙永涛 孙江平 李敬云
吴尊友 张 彤 陈祥生
金 曦 庞 宇 郑和义
赵红心 蒋 岩 蔡卫平
廖苏苏 翟晓梅

编 委：（以姓氏笔画为序）
王 哲 王 璐 王千秋
王开利 王立秋 王临虹
方利文 尹跃平 邢 辉
邢文革 曲书泉 朱效科
刘 民 刘 惠 刘水青
刘志民 刘康迈 严延生
苏 斌 李 勇 李宏军
李现红 李惠琴 还锡萍
何 纳 何盛华 沈银忠
沈智勇 宋玉霞 张北川
张庆宁 张灵麟 陈 琳
陈 曦 陈素良 林 鹏
周 林 赵 敏 钟 平
姚文清 贺 雄 贾曼红
徐 杰 徐立然 徐俊杰
凌 华 龚向东 康殿民
梁国钧 傅继华 蔺秀云
潘启超

责任编辑：郑京婵 刘 霞
校 对：王晓春 张 蕊
英文审校：张 云

如有印装质量问题，请向本刊
编辑部调换

工作研究

青少年性身份认同的科普教育研究……………黄耳，张爱迪，严谨（298）
德州市长途卡车运输司机艾滋病防治相关知识知晓率及其影响
因素分析……………姜明东，胡玉宏，夏永惠，王壮业，张晓菲，吕翠霞，赵琳（301）
上海市松江区 2006 — 2015 年梅毒流行病学分析
……………潘新健，罗珍，郭晓芹（305）

短篇报道

男男性行为者定期艾滋病咨询检测动机及态度的定性研究
……………肖绍坦，陈盼盼，辛辛（308）
武汉地区新报告 ≥ 50 岁 HIV/AIDS 病人高危行为特征
……………罗莉，胡荣，许骏，曹琳，王夏（310）
2008 — 2018 年嘉峪关市艾滋病报告疫情特征
……………张晴雯，王玉明（312）

病例报告

1 例 HIV 感染者抗病毒治疗后蛋白印迹试验结果变化的追踪报告
……………朱丹，刘杨，朱厚宏（314）
舌体部位硬下疳 1 例……………高晓莉，武铮，周向昭（316）

综 述

HIV 相关神经认知功能障碍的发病机制及诊断研究进展
……………刘婷，谭继英，侯宗婕，张蕊，乔成栋（317）
HIV/AIDS 病人的眼部并发症……………史少阳，王宇，包娟（321）
我国 ≥ 50 岁男性艾滋病感染危险因素研究进展……………刘丹丹，曹晓斌（325）
淋球菌抵抗中性粒细胞杀伤机制研究进展……………郑晓丽，尹跃平，周可（327）

专家共识

人类免疫缺陷病毒（HIV）抗病毒治疗二联简化疗法专家共识……………王辉，
李在村，赵红心，孙丽君，赵清霞，何盛华，刘水青，蔡卫平，李凌华，
沈银忠，李惠琴，郭彩萍，吕玮，陈耀凯，宋玉霞，张福杰（331）
HIV 阳性孕产妇全程管理专家共识……………孙丽君，王爱玲，张福杰，吴昊，
赵红心，王辉，王前，王敏，刘水青，宋玉霞，陈耀凯，庞俊，赵清霞，
喻剑华，蔡琳，李凌华，何浩岚，李在村，黄晓婕，张宏伟，刘安，蔡卫平（335）

本期审稿专家：（以姓氏笔画为序）

王千秋 毛宇嵘 方利文 邢 辉 邢文革 曲书泉 吕 繁
乔亚萍 刘 惠 刘康迈 李敬云 汪 宁 沈银忠 张北川
陈素良 罗 巍 周 林 庞 琳 赵 敏 钟 平 黄辉煌
龚向东 梁国钧 蔡卫平

本刊得到深圳市疾病预防控制中心多年的支持

本刊投稿网址：<http://xbya.cbpt.cnki.net/>
期刊基本参数：CN11-4818/R*1995*m*A4*112*zh*p*¥ 20.00*2 600*31*2020-03

CHINESE JOURNAL OF AIDS & STD

Published monthly Since August 1995 Vol. 26 No. 3 March 26, 2020

Competent Authority
National Health Commission of
the People's Republic of China

Sponsor
Chinese Association of STD &
AIDS Prevention and Control

Editor in Chief
SHEN Jie

Managing Director
LIU Xia

Published by
Editorial Department of Chinese
Journal of AIDS & STD
27 Nanwei Road, Xicheng District,
Beijing 100050, China
Tel. 86-010-63030828
Fax. 86-010-63030028
Email: aidsbjb@126.com
aids2006@sina.com

Printed by
October Printing(Beijing)Co.,Ltd.

Distribution
Domestic distributor:
Beijing Municipal Bureau of
Newspaper and Journal Distribution

Overseas distributor:
China International Book
Trading Corporation
P. O. Box 399, Beijing
100044, China
Code No. M 6559

Subscription
Post offices all over the country
Code No. 82-912

CSSN
ISSN 1672-5662
CN 11-4818/R

Contents in Brief

Comparative study of total HIV DNA in HIV/AIDS patients in different disease courses.....LIU Jia, YAN Jiangzhou, XUE Xiujuan, LIU Chunhua, SUN Guoqing, TIAN Suian, SUN Dingyong, WANG Zhe (227)

Relationship between CD4⁺ T cell, HIV DNA and HIV RNA in PBMCs of HIV-infected patients.....PAN Kenv, ZHANG Yongle, YU Wenyan, XUE Lizhi (231)

Effect of anti-tuberculosis treatment on HIV/TB co-infected patients with anti-HIV therapy.....SHU Yuanlu, YANG Cuixian, DONG Xingqi, ZHANG Mi, LI Jianjian, YANG Bihui, LIU Jiafa, DENG Xuemei, ZHANG Wei, YAN Yan (234)

Comparison of diagnostic methods for latent tuberculosis infection among HIV-infected people in high HIV prevalence areas.....HUANG Huan, GAO Wenfeng, SU Qian, LI Jing, LI Ting, LI Yunkui, WANG Chuan, GAO Yuan, XU Jinchuan, LIAO Zhihong, HE Jing, YANG Wen (239)

Physical performance and analytical sensitivity of rapid diagnostic test reagents sold online to screen HIV infection.....REN Yanan, MA Zhonghui, XU Bing, WANG Jun, PEI Lijian, JIANG Yan, XING Wenge (243)

Current status of hepatitis C diagnosis and treatment in Chinese medical institutions.....FENG Xiaofei, DING Guowei, YU Hailiang, PAN Ling, GAO Yu, TANG Yang, MAO Yurong, PANG Lin (247)

Hepatitis C sero-epidemiological study among attendants in four general hospitals of Zhejiang province.....JIANG Jun, PAN Xiaohong, YANG Jiezhe, HONG Hang, XU Yuanyuan, WANG Bin, SHI Xiaojun, YE Xiaohong, CHEN Qiaoming (250)

Prevalence of HIV drug resistance among pregnant women.....SHEN Rui, PAN Xiaoping, WANG Ailing, WANG Xiaoyan, QU Shuiling, ZHANG Tong (254)

Analysis of knowledge awareness and service acceptance of HIV non-occupational post-exposure prophylaxis (nPEP) among students in three cities of China.....SHAO Ying, LI Jie, LIU An, YU Yanping, CHEN Ziliang, JIANG Tianjun, SONG Bing, WANG Hui, LIU Xiaoning, LIU Jun, ZHANG Guang (259)

Characteristics of HIV-positive pregnant women and effect of prevention of mother-to-child HIV transmission in Shenzhen from 2009 to 2018.....TIAN Yimei, LIANG Meixin, SONG Junmin, YANG Zhengrong, ZHOU Jie, WANG Hong, BAO Mingwen, WANG Hui (264)

HIV-1 gene diversity and related factors in MSM population in Beijing.....ZHOU Zhihan, ZHANG Jing, XIN Ruolei, RUAN Yuhua, LU Hongyan, FENG Yi, KANG Ruihua, LIAO Lingjie, SHAO Yiming, XING Hui (268)

HIV-1 transmission characteristics among men who have sex with men in Guangdong.....ZHOU Pingping, YU Guolong, LIU Jun, FU Xiaobing, LI Yan, HUANG Xuhe, LIN Peng, YAN Jin, HE Xiang (273)

AIDS prevention community activities participated by men who have sex with men and the associated factors in Mianyang city.....WANG Yi, LI Liulin, FAN Jing, ZHAO Xihe, WANG Xiaoli, LI Jun, YANG Ganjin, LI Wei, JIA Xiuwei, LIU Xiaoqin, DU Chanjuan, REN Yanfei, LIAO Ping (277)

Sexual behaviors of HIV positive married MSM in Changde and Zhangjiajie, China.....HUANG Daoping, CHI Yuanyuan, ZHOU Jing, LI Yajuan, LI Xianhong (281)

Effects of childhood trauma on psychotic-like experiences in 191 HIV infected men who have sex with men.....WANG Dongfang, ZHOU Bai, GAO Yulian, YANG Xinhua, WANG Min, OUYANG Xuan, LIU Zhening, WANG Honghong (286)

Influenial factors of late diagnosis among newly detected HIV/AIDS cases during 2008-2018 in Wuhan, Hubei province.....DING Jie, YAN Han, WU Si, WANG Xia, XIE Nianhua (290)

Knowledge, related behavior and HIV infection among Mosuo people, in Yunnan province.....SONG Lijun, ZHANG Xuhong, LU Yanning, SHA Penglian, XIAO Mingyang, FU Liru, NIU Jin, LI Xuehua, LUO Hongbing (294)

Research on adolescents' sexual identity education.....HUANG Er, ZHANG Aidi, YAN Jin (298)

Knowledge awareness and influencing factors of AIDS prevention and treatment among long-distance truck drivers in Dezhou city.....JIANG Mingdong, HU Yuhong, XIA Yonghui, WANG Zhuangye, ZHANG Xiaofei, LYU Cuixia, ZHAO Lin (301)

Epidemiological analysis of syphilis from 2006 to 2015 in Songjiang district, Shanghai.....PAN Xinjian, LUO Zhen, GUO Xiaoqin (305)

Advances of pathogenesis and diagnosis in HIV-associated neurocognitive disorder.....LIU Ting, TAN Jiying, HOU Zongjie, ZHANG Rui, QIAO Chengdong (317)

Ocular complications of HIV/AIDS patients.....SHI Shaoyang, WANG Yu, BAO Juan (321)

Research progress on risk factors of HIV/AIDS infection in men aged 50 years and over in China.....LIU Dandan, CAO Xiaobin (325)

Latest progress on neutrophil killing mechanism of Neisseria gonorrhoeae.....ZHENG Xiaoli, YIN Yueping, ZHOU Ke (327)

诊断;当怀疑有急性 HIV 感染时,需要加用 HIV 核酸检测进行诊断。

如果根据 2 次核酸检测来诊断或者排除婴儿 HIV 感染,必须在出生 18~24 个月进行 HIV 抗体检测来证实。

参考文献:

[1] Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study[J]. *Lancet*, 2003, 362(9377): 22–29.

[2] World Health Organization HIV/AIDS. WHO 2018. [EB/OL].(2019)[2019–09–11]. Available at <http://www.who.int/mediacentre/factsheets/fs360/en/> (Accessed 30 June 2019).

[3] Nesheim SR, Wiener J, Fitz Harris LF, et al. Brief report: estimated incidence of perinatally acquired HIV infection in the United States, 1978 – 2013 [J]. *J Acquir Immune Defc Syndr*, 2017,76(5):461–464.

[4] Peters H, Francis K, Sconza R, et al. UK mother-to-child HIV transmission rates continue to decline: 2012 – 2014 [J]. *Clin Infect Dis*, 2017,64(4):527–528.

[5] 中华医学会感染病学分会艾滋病丙型肝炎学组, 中国疾病预防控制中心. 中国艾滋病诊疗指南 (2018 版) [J]. *中华临床感染病杂志*, 2018,11(6):411–432.

[6] Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United State[EB/OL]. [2019–11–07]. <http://aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL.pdf>.

[7] Gaynes BN, Gavin N, Meltzer–Brody S, et al. Perinatal Depression: Prevalence, Screening Accuracy, and Screening Outcomes [J]. *Evidence Report/Technology Assessment(Summary)*, 2005,119(119):1–8.

[8] Kapetanovic S, Christensen S, Karim R, et al. Correlates of Perinatal Depression in

HIV-Infected Women[J]. *AIDS Patient Care STDS*, 2009,23(2):101–108.

[9] Sheth SS, Coleman J, Cannon T, et al. Association between depression and nonadherence to antiretroviral therapy in pregnant women with perinatally acquired HIV[J]. *AIDS Care*, 2015,27(3):350–354.

[10] Ammassari A, Antinori A, Aloisi MS, et al. Depressive Symptoms, Neurocognitive Impairment, and Adherence to Highly Active Antiretroviral Therapy Among HIV-Infected Persons[J]. *Psychosomatics*, 2004,45(5):394–402.

[11] European AIDS Clinical Society. EACS Guidelines (Version 9.0)[EB/OL]. [2019–11–19]. http://www.eacsociety.org/files/guidelines_9.0-english.pdf.

[12] International Perinatal HIV Group. The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1—a meta-analysis of 15 prospective cohort studies [J]. *N Engl J Med*, 1999,340(13):977–987.

[13] 崔富强, 庄辉. 中国乙型肝炎的流行及控制进展 [J]. *中国病毒病杂志*, 2018,8(4): 257–264.

[14] Wong VV. Is peripartum zidovudine absolutely necessary for patients with a viral load less than 1,000 copies/mL [J]. *J Obstet Gynaecol*, 2011,31(8):740–742.

[15] Committee on Obstetric Practice, HIV Expert Work Group. ACOG Committee Opinion No. 751: labor and delivery management of women with Human Immunodeficiency Virus infection [J]. *Obstet Gynecol*, 2018,132(3):e131 –e137.

[16] 国家卫生和计划生育委员会办公厅. 国家卫生和计划生育委员会办公厅关于全面开展预防艾滋病、梅毒和乙肝母婴传播工作的通知 [EB/OL].(2015–06–16)[2019–09–11]. <http://www.nhfp.gov.cn/fys/s3581/201506/4f2123fa955a44afa75a75da2ad35d6e.shtml>.

[17] Centers for Disease Control and Prevention and Association of Public Health Laboratories. Laboratory testing for the diagnosis of HIV infection: updated recommendations[EB/OL]. (2014–06–27)[2019–09–11]. Available at: <http://dx.doi.org/10.15620/cdc.23447>.

[18] Gutierrez M, Ludwig DA, Khan SS, et al. Has Highly Active Antiretroviral Therapy Increased the Time to Seroreversion in HIV Exposed but Uninfected Children[J]. *Clinical Infectious Diseases*, 2012,55(9):1255–1261.

(上接第 334 页)

[24] Aboud M, Orkin C, Podzamecz D, et al. Efficacy and safety of dolutegravir – rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies[J]. *The Lancet HIV*, 2019,6(9):e576–e587.

[25] Pulido F, Ribera E, Lagarde M, et al. Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial[J]. *Clin Infect Dis*, 2017(65):2112–2118.

[26] Perez-Molina JA, Rubio R, Rivero A, et al. Simplification to dual therapy (atazanavir/ritonavir + lamivudine) versus standard triple therapy [atazanavir/ritonavir + two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)[J]. *J Antimicrob Chemother*, 2017(72):246–253.

[27] Arribas JR, Girard PM, Landman R, et al. Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial[J]. *Lancet Infect Dis*, 2015(15):785–792.

[28] Maggiolo F, Di Filippo E, Valenti D, et al. NRTI Sparing Therapy in Virologically Controlled HIV-1 Infected Subjects: Results of a Controlled, Randomized Trial (Probe)[J]. *J Acquir Immune Defc Syndr*, 2016(72):46–51.

[29] WHO. Update of recommendations on first-and-second-line antiretroviral regimens [EB/OL].(2019)[2020–02–25]. <https://www.who.int/hiv/pub/arv/arv-update-2019-policy/en/2019>.

[30] Navarro J, Santos JR, Silva A, et al. Effectiveness of once/day dolutegravir plus boosted darunavir as a switch strategy in heavily treated patients with human immunodeficiency virus[J]. *Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy*, 2019, 39(4): 501–507.

[31] Jablonowska E, Siwak E, Bociaga-Jasik M, et al. Real-life study of dual therapy based on dolutegravir and ritonavir-boosted darunavir in HIV-1-infected treatment-experienced patients[J]. *PLoS One*, 2019(14):1.

[32] van Lunzen J, Pozniak A, Gatell JM, et al. Brief Report: Switch to Ritonavir-

Boosted Atazanavir Plus Raltegravir in Virologically Suppressed Patients With HIV-1 Infection: A Randomized Pilot Study[J]. *J Acquir Immune Defc Syndr*, 2016(71):538–543.

[33] Pett SL, Amin J, Horban A, et al. Maraviroc, as a Switch Option, in HIV-1-infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH Study[J]. *Clin Infect Dis*, 2016(63):122–132.

[34] Katlama C, Assoumou L, Valantin MA, et al. Maraviroc plus raltegravir failed to maintain virological suppression in HIV-infected patients with lipohypertrophy: results from the ROCnRAL ANRS 157 study[J]. *J Antimicrob Chemother*, 2014(69):1648–1652.

[35] Cheung CY, Wong KM, Lee MP, et al. Prevalence of chronic kidney disease in Chinese HIV-infected patients[J]. *Nephrol Dial Transplant*, 2007(22):3186–3190.

[36] Cao Y, Han Y, Xie J, et al. Impact of a tenofovir disoproxil fumarate plus ritonavir-boosted protease inhibitor-based regimen on renal function in HIV-infected individuals: a prospective, multicenter study[J]. *BMC Infect Dis*, 2013(13):301.

[37] Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review[J]. *AIDS*, 2006(20):2165–2174.

[38] Bowman E, Funderburg NT. Lipidome abnormalities and cardiovascular disease risk in HIV infection[J]. *Current HIV/AIDS Reports*, 2019,16(3): 214–223.

[39] Postorino MC, Quiros-Roldan E, Maggiolo F, et al. Exploratory Analysis for the Evaluation of Estimated Glomerular Filtration Rate, Cholesterol and Triglycerides after Switching from Tenofovir/Emtricitabine plus Atazanavir/Ritonavir (ATV/r) to Abacavir/Lamivudine plus ATV/r in Patients with Preserved Renal Function[J]. *Open AIDS J*, 2016(10):136–143.

[40] Randell P, Jackson A, Milinkovic A, et al. An open-label, randomized study of the impact on insulin sensitivity, lipid profile and vascular inflammation by treatment with lopinavir/ritonavir or raltegravir in HIV-negative male volunteers[J]. *Antivir Ther*, 2017(22):145–151.

[41] Zash R, Holmes L, Diseko M, et al. Neural-Tube Defects and Antiretroviral Treatment Regimens in Botswana[J]. *N Engl J Med*, 2019(381):827–840.